Thursday, 13 Dec 2018

You are here

Seronegative and Seropositive Rheumatoids Respond Equally Well

A cohort study of 241 DMARD-naive rheumatoid arthritis (RA) patients, meeting either 1987 ACR or the 2010 ACR/EULAR  classification criteria for RA, compared the baseline status and long term outcomes of seronegative (SNRA) and seropositive (SPRA).

While it is well-known that RA patients seropositive for either rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) may have more aggressive disease and poorer radiologic outcomes, the fate of SNRA patients is less well characterized.

They compared 40 patients with SNRA and 201 with SPRA and looked at clinical and X-ray findings at baseline and after 1 and 2 years of conventional DMARD treatment.

While age, sex and disease duration were similar between SNRA and SPRA, at baseline SNRA patients had higher median tender joint counts (4.7±2.9 vs. 3.3±2.7, p = 0.004), swollen joint counts (4.3±3.0 vs. 2.9±2.3, p = 0.001) and DAS28 scores (5.1±1.0 vs. 4.7±1.0, p = 0.043). Such findings have been noted in other cohort studies and suggests that SNRA patients will require quantitatively more joint activity to meet the RA classification criteria. 

After 2 years of DMARDs therapy, all patients and measures and X-ray outcomes improved equally.  But the change in disease activity (ΔDAS28) was only greater at 1 year when comparing SNRA and SPRA (-2.84±1.32 vs. -3.70±1.29, p = 0.037) in high disease activity population (DAS28-ESR>5.1).

These data suggest that while SNRA patients may have more disease activity and more joints early in the disease, they appear to respond equally well to conventional DMARD therapy.

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

In my in locum adventures, I see a lot of SNRA patients years after the diagnostic label was assigned to them by a former rheumatologist. Truthfully, undifferentiated or inflammatory arthritis (assuming it is steroid responsive) is a better diagnosis in the first 1-2 years before SNRA is assigned that future providers assume is a secure diagnosis.

More Like This

CV Risks Similar in Systemic Sclerosis and Rheumatoid Arthritis

Interactions between disease-related inflammatory processes and the development of several morbidities have been well-studied in RA, particularly heart disease. This is not the case for the often-lethal SSc (estimated standardized mortality ratio between 2.5 and 4.0). Similarly, there are no studies comparing the most relevant comorbidities between SSc and RA.

PRAIRI Study - Can RA Be Prevented?

B-cell depletion may offer a means of delaying the onset of clinical arthritis in adults at high risk, according to the PRAIRI study - a proof-of-mechanism study in pre-clinical RA patients. 

Rheumatoid Lung Disease Imposes Significant Morbidity and Mortality

Insurance claims data were analyzed for the frequency of interstitial lung disease (ILD) associated with rheumatoid arthritis (RA) and finds that although rare, its frequency increased over time and it is associated with a significant mortality rate. 

The study was done because RA-ILD has been shown to cause significant morbidity and mortality. 

Growing Tick Population Comes with Health Concerns

CNN has published a recent government report from the Tick-Borne Disease Working Group that suggests the US tick population is growing and may bring with it an increase in tick-related illnesses. 

While Lyme disease is the most popular of tick-borne illnesses, there are another 20 known conditions related to tick bites.

Chikungunya Virus Vaccine Developed

Lancet reports on a new vaccine for Chikungunya fever (MV-CHIK) demonstraing excellent safety, tolerability and good immunogenicity, independent of pre-existing immunity against the vector. MV-CHIK is a promising vaccine for the prevention of chikungunya fever.